Merck launches new membrane plant in Ireland, opening new jobs

Satellite image of Ireland

Merck ($MRK) recently unveiled a new manufacturing and R&D facility in Carrigtwohill, County Cork, Ireland that represents a $62 million investment and the creation of up to 70 new positions. 

The specialty membrane facility will take over all development of membrane work for the German drug company in the wake of the closing of a plant in the U.S.,” Martin McAuliffe, the company’s site leader, told the Irish Times.

“We are adding R&D capability to develop and scale up,” he said. “We also do antibody development onsite.”

Merck didn’t respond to a FiercePharmaManufacturing request about details concerning the closure of the U.S. plant.

McAuliffe added that the small number of R&D employees at the facility now will “grow substantially” in the next few years. There are currently about 700 staff at the Cork site. 

“In the past, scale-up and development of new membranes would be done in the U.S.,” he said. “We have a facility there that’s closing at the end of the year.”

The recent expansions by Merck in Ireland stand in stark contrast to the deep cuts the company made three years ago when it closed a plant in Rathdrum and trimmed jobs at its API plant in Brinny.

- here’s the Irish Times story


Suggested Articles

Indian pharma Wockhardt signed on to churn out millions of U.K. vaccines through its North Wales subsidiary, including doses of AstraZeneca's hopeful.

After global recalls of heartburn medicine Zantac and an FDA ban, the Department of Justice is investigating Sanofi and GlaxoSmithKline.

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.